[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 1958

Azacyclonol (Frenquel) in Chronic Schizophrenia: Objective Measurement of Its Effects

AMA Arch NeurPsych. 1958;80(3):388-393. doi:10.1001/archneurpsyc.1958.02340090124018

Introduction  Since studies on azacyclonol first appeared in the literature, in 1955, many investigators have praised azacyclonol as an anticonfusional, antidelusional, and antihallucinatory drug. Cohen and Parlour6 have claimed that azacyclonol is as effective an ataraxic agent as chlorpromazine or reserpine. Most descriptions of the effects of azacyclonol have been ambiguous and subjective. Results are frequently reported in such vague terms as "complete remission," "greatly improved," or, simply, "improved." However, three studies using a double-blind cross-over design2729 have also indicated beneficial effects of azacyclonol. A minority of studies have shown azacyclonol to be ineffective,3,16,24,30,32,35 including a well-designed study done with a double-blind technique by Peak, Canestrari, and Roebuck,24 which showed no significant difference between azacyclonol and placebo groups of chronic schizophrenic patients. Cutler, Monroe, and Anderson,7,8 in studying the effects of "tranquilizers" upon pathological behavior in schizophrenics, have stressed the importance of doing adequately controlled